We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+8.27%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$21.8B
AUM Growth
+$3.36B
Cap. Flow
+$2.78B
Cap. Flow %
12.74%
Top 10 Hldgs %
12.04%
Holding
3,109
New
1,280
Increased
559
Reduced
519
Closed
699

Sector Composition

Rank Sector Weight
1 Healthcare 20.03%
2 Consumer Discretionary 13.15%
3 Technology 10.68%
4 Financials 9.81%
5 Communication Services 8.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
XOMA
1876
DELISTED
Xoma
XOMA
$586K ﹤0.01%
14,350
-1,522
-10% -$58.9K
SPNE
1877
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$586K ﹤0.01%
33,674
-26,830
-44% -$481K
WIRE
1878
DELISTED
Encore Wire Corp
WIRE
$585K ﹤0.01%
8,715
-48,988
-85% -$3.17M
IYR icon
1879
PUT
iShares US Real Estate ETF
IYR
$4.76B
$579K ﹤0.01%
6,300
-265,200
-98% -$23.3M
MBII
1880
DELISTED
Marrone Bio Innovations, Inc.
MBII
$577K ﹤0.01%
+276,305
New +$574K
MACK
1881
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$576K ﹤0.01%
91,766
+35,918
+64% +$257K
L icon
1882
Loews
L
$24.6B
$574K ﹤0.01%
+11,202
New +$546K
KYMR icon
1883
Kymera Therapeutics
KYMR
$8.73B
$571K ﹤0.01%
+14,698
New +$885K
SWBK.U
1884
DELISTED
Switchback II Corporation Units, each consisting of one Class A ordinary share and one fifth of one
SWBK.U
$570K ﹤0.01%
+56,025
New +$647K
KTB icon
1885
Kontoor Brands
KTB
$4.87B
$569K ﹤0.01%
+11,726
New +$524K
AUTL
1886
Autolus Therapeutics
AUTL
$386M
$568K ﹤0.01%
+99,013
New +$733K
STX icon
1887
Seagate
STX
$169B
$568K ﹤0.01%
+7,405
New +$515K
FFWM
1888
DELISTED
First Foundation Inc
FFWM
$565K ﹤0.01%
24,082
+1,788
+8% +$40K
TUFN
1889
DELISTED
Tufin Software Technologies Ltd.
TUFN
$565K ﹤0.01%
+53,758
New +$754K
HYFM icon
1890
Hydrofarm Holdings
HYFM
$3.17M
$560K ﹤0.01%
+928
New +$651K
VEEV icon
1891
Veeva Systems
VEEV
$32.7B
$560K ﹤0.01%
+2,146
New +$598K
MOMO
1892
Hello Group
MOMO
$869M
$557K ﹤0.01%
+37,770
New +$611K
CSX icon
1893
CSX Corp
CSX
$94.2B
$555K ﹤0.01%
17,277
-202,539
-92% -$6.18M
DIS icon
1894
CALL
Walt Disney
DIS
$172B
$554K ﹤0.01%
+3,000
New +$553K
CACC icon
1895
Credit Acceptance
CACC
$5.84B
$550K ﹤0.01%
+1,527
New +$554K
ANIK icon
1896
Anika Therapeutics
ANIK
$202M
$546K ﹤0.01%
+13,383
New +$508K
TCDA
1897
DELISTED
Tricida, Inc. Common Stock
TCDA
$546K ﹤0.01%
+103,282
New +$649K
FIZZ icon
1898
National Beverage
FIZZ
$3.05B
$544K ﹤0.01%
11,128
-17,548
-61% -$912K
LYRA
1899
DELISTED
LYRA THERAPEUTICS INC
LYRA
$544K ﹤0.01%
939
+658
+234% +$411K
TLPH icon
1900
Talphera
TLPH
$67.5M
$543K ﹤0.01%
+15,968
New +$634K

Similar funds

Marshall Wace's Q1 2021 Portfolio in Review

As of Q1 2021, Marshall Wace held 3,109 positions worth $21.8B, up 18% from $18.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Marshall Wace deployed $2.78B of net new capital in Q1 2021, opening 1,280 new positions and adding to 559 existing holdings. Its largest new stake was Paramount Global Class B: 5,936,494 shares worth $268M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $204M trimmed.

  • Marshall Wace's largest Q1 2021 buy was Paramount Global Class B: 5,936,494 shares worth $268M.
  • Marshall Wace added most to Farfetch Limited Class A Ordinary Shares in Q1 2021, an estimated $182M increase.
  • Marshall Wace's biggest Q1 2021 reduction was Thermo Fisher Scientific, cutting an estimated $204M.
  • Marshall Wace fully exited Vanguard Intermediate-Term Corporate Bond ETF in Q1 2021, selling an estimated $76.2M.
  • Marshall Wace's ten largest holdings make up 12% of its $21.8B portfolio in Q1 2021.
  • Marshall Wace opened 1,280 new positions and closed 699 in Q1 2021.
  • Marshall Wace's portfolio value rose 18% quarter-over-quarter to $21.8B.

Based on Marshall Wace's 13F filing for Q1 2021, filed 17 May 2021.